About this trial
This study, which is aimed at comparing the effectiveness of the most frequently used drugs in the first line in primary care for the preventive treatment of migraine (amitriptyline, flunarizine, topiramate and propranolol), is a multicentre, pragmatic, parallel group, open randomised trial. Adults (≥18) candidates for preventive treatment for migraine; those with a frequency of ≥4 monthly migraine days, and who agree to participate in the clinical trial, will be randomised to one of the 4 groups. Sample: 460 patients. The primary outcome will be the reduction in monthly migraine days, comparing amitriptyline, flunarizine and topiramate with propranolol.
Eligibility criteria
Qualifiers
None
Disqualifiers
People diagnosed with migraine who are not candidates for preventive migraine treatment
People diagnosed with chronic migraine (>15 days of headache per month, of which 8 are monthly migraine days)
Not having a smartphone
Simultaneous participation in another clinical trial
Trial design
Treatments tested in this trial
- Topiramate
- Flunarizine
- Amitriptyline
- Propranolol
Treatment groups
Locations
Sponsors and collaborators
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Lead sponsor
Institut Català de la Salut
Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborator